Study of SAB-176 in Healthy Adult Participants
Trial details
- Registry ID
- NCT04850898
- Phase
- Phase 2
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of SAB-176 in Healthy Adult ParticipantsNCT04850898 | SABS | Phase 2 | Completed | 2021-10-08Actual |
| SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 DiabetesNCT07187531 | SABS | Phase 2 | Recruiting | 2027-11Estimated |
NCT07187531 · SAb Biotherapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Measure: Part A: Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs) Measure: Part B: Area under the concentration-time curve (AUC) of C-peptide after a 2 hour mixed meal tolerance test (MMTT)
Measure: Part A: Incidence of treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs) Measure: Part B: Area under the concentration-time curve (AUC) of C-peptide after a 2 hour mixed meal tolerance test (MMTT) Measure: Part C: Area under the concentration-time curve (AUC) of C-peptide after a 2-hour mixed meal tolerance test (MMTT).
NCT07187531 · SAb Biotherapeutics, Inc.
Not yet recruiting
Recruiting